MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindMed commences LSD microdosing study on various health-and-wellness benefits.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now